Business Context and Reporting Period
Company: Mineralys Therapeutics, Inc. (MLYS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Mineralys is a biopharmaceutical company developing lorundrostat, an investigational aldosterone synthase inhibitor for uncontrolled/resistant hypertension. The company submitted a New Drug Application (NDA) to the FDA in December 2025, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026. The company has no product revenue and operates as a pre-commercial entity.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(280,410) | $(85,485) |
| Net Loss Per Share (Basic & Diluted) | $(3.35) | $(1.44) |
| Operating Expenses | $291,380 | $91,193 |
| Research & Development (R&D) | $245,742 | $76,157 |
| General & Administrative (G&A) | $45,638 | $15,036 |
| Interest Income, Net | $10,952 | $5,713 |
| Cash, Cash Equivalents, and Investments | $661,412 | $597,805 |
| Long-Term Debt (Senior Secured Term Loan) | $97,617 | $0 |
| Accumulated Deficit | $(737,579) | $(388,003) |
Note: Cash, cash equivalents, and investments as of June 30, 2026, totaled $661.4 million ($138.3 million cash/cash equivalents + $523.1 million investments).
Material Changes vs. Prior Period
- Significant Increase in R&D Expenses: R&D expenses increased by $169.6 million (223%) year-over-year. This was primarily driven by a $200.0 million upfront cash payment to Tanabe Pharma Corporation in June 2026 under the Fourth Amendment to the License Agreement. This payment converted the license to royalty-free and perpetual.
- Debt Financing: The company entered into a Senior Secured Term Loan agreement in June 2026, drawing $100.0 million (Tranche A). This represents a new liability not present in the prior period.
- Equity Financing: The company raised approximately $143.6 million in net proceeds from a public offering of 5.66 million shares in June 2026 and $20.2 million via its At-The-Market (ATM) program during the six months ended June 30, 2026.
- Cash Flow: Net cash used in operating activities was $72.0 million, compared to $75.7 million in the prior year. Net cash used in investing activities increased to $230.2 million, largely due to the $200.0 million Tanabe payment. Net cash provided by financing activities increased to $267.5 million due to the new debt and equity issuances.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes cash, cash equivalents, and investments of $661.4 million are sufficient to fund operations, including the commercial launch of lorundrostat, for at least twelve months from the filing date.
- Regulatory Milestone: The FDA PDUFA target date for the lorundrostat NDA is December 22, 2026. Approval is required to trigger the draw of the Tranche B Loan ($150 million) and to generate product revenue.
- Debt Covenants and Risks:
- The Term Loan matures in 2031 but accelerates to June 30, 2028, if the FDA does not approve the NDA by September 30, 2027.
- The loan is secured by substantially all company assets, including intellectual property.
- Financial covenants include a minimum liquidity requirement and a future minimum trailing twelve-month net product revenue covenant (tested starting fiscal year 2028).
- Future Milestones: The company has remaining obligations to pay Tanabe up to $255.0 million in commercial milestones upon first commercial sale and meeting annual sales targets.
- Market Risk: The company is exposed to variable interest rate risk on the Term Loan (SOFR + 5.50%). A 1% change in rates would impact annual interest expense by approximately $1.0 million.
Investor Verification Checklist
- Tanabe License Amendment: Verify the terms of the Fourth Amendment, specifically the $200 million upfront payment and the elimination of royalty obligations, and confirm the remaining $255 million in contingent commercial milestones.
- Debt Structure: Review the Senior Secured Term Loan agreement details, specifically the acceleration clause tied to the September 30, 2027, FDA approval deadline and the security interest in IP assets.
- Capital Runway: Assess the $661.4 million cash position against the projected burn rate, considering the upcoming commercial launch costs and the potential need to draw the remaining $400 million in debt tranches.
- Regulatory Timeline: Monitor the FDA review process for the lorundrostat NDA submitted in December 2025, with a target decision date of December 22, 2026.
- Equity Dilution: Track the remaining capacity under the ATM agreement ($187.2 million available) and potential future equity issuances required to fund operations if revenue does not materialize as planned.